0001209191-20-021382.txt : 20200327 0001209191-20-021382.hdr.sgml : 20200327 20200327161526 ACCESSION NUMBER: 0001209191-20-021382 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190830 FILED AS OF DATE: 20200327 DATE AS OF CHANGE: 20200327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Menzel Garry E CENTRAL INDEX KEY: 0001556064 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38811 FILM NUMBER: 20751982 MAIL ADDRESS: STREET 1: C/O REGULUS THERAPEUTICS INC. STREET 2: 3545 JOHN HOPKINS COURT SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC. CENTRAL INDEX KEY: 0001750019 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474152751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-5200 MAIL ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-08-30 0 0001750019 TCR2 THERAPEUTICS INC. TCRR 0001556064 Menzel Garry E C/O TCR2 THERAPEUTICS 100 BINNEY STREET CAMBRIDGE MA 02142 1 1 0 0 President & CEO Common Stock 84527 I See footnote 1 Common Stock 2019-08-30 5 A 0 E 980 12.75 A 980 D Common Stock 2020-02-28 5 A 0 E 1287 10.10 A 2267 D Consists of 84,527 shares of common stock held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 13, 2019 through August 30, 2019. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 13, 2019. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 2, 2019 through February 28, 2020. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020. /s/ Margaret Siegel as Attorney-in-Fact 2020-03-27